Mingyang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingyang Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jie Ni
University of Innsbruck
2 shared publications - Yuhan Cai
State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, Jiangsu, China
2 shared publications - Zhuoying Xie
School of Biological Science & Medical Engineering, Southeast University, Nanjing 210096, China
2 shared publications Bin Li
Institute of Microphysiological Systems, State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China
1 shared publication- Bing Wang
Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, Institute of Precision Medicine, School of Medical Technology and Engineering
1 shared publication - Dong Wei
Institute of Microphysiological Systems, State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China
1 shared publication
Latest Publications
- 9 October 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 126 (Pt 2) , 109480
Benchmarking biological knowledge-graph priors against single-cell foundation models for Perturb-seq prediction
- 9 October 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 126 (Pt 2) , 109480
Benchmarking biological knowledge-graph priors against single-cell foundation models for Perturb-seq prediction
- Open Access
- 16 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7646
A functionally tunable magnetic nanochains platform for N-glycoproteomic analysis of extracellular vesicles from ultratrace biofluids
Extracellular vesicles (EVs) carry complex glycoproteins critical mediators of disease progression and hold great potential for liquid biopsy applications. However, their low abundance presents significant analytical challenges. This study develop a versatile platform for EV N-glycoproteomic analysis (EVGpro), which enables tandem EV capture, EV protein digestion, and enrichment of N-glycopeptides. Functionalized magnetic nanochains with cell-penetrating peptides (octa-arginine, R8) enable efficient EV isolation, followed by on-chain hydrolysis to expose PEG2000 for ultrasensitive glycopeptide enrichment. The streamlined EVGpro platform identified up to 17 times more EV glycoproteins than ultracentrifugation across seven biofluids, profiling 398 EV glycoproteins from just 1 μL tear. Applied to seminal plasma, EVGpro uncover disease-specific glycoprotein signatures and identified previously unreported subtypes of asthenozoospermia. This robust and scalable approach advances the sensitive detection of disease biomarkers and molecular subtypes from diverse biofluids to enable precision medicine.
- 16 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7646
Open AccessA functionally tunable magnetic nanochains platform for N-glycoproteomic analysis of extracellular vesicles from ultratrace biofluids
Extracellular vesicles (EVs) carry complex glycoproteins critical mediators of disease progression and hold great potential for liquid biopsy applications. However, their low abundance presents significant analytical challenges. This study develop a versatile platform for EV N-glycoproteomic analysis (EVGpro), which enables tandem EV capture, EV protein digestion, and enrichment of N-glycopeptides. Functionalized magnetic nanochains with cell-penetrating peptides (octa-arginine, R8) enable efficient EV isolation, followed by on-chain hydrolysis to expose PEG2000 for ultrasensitive glycopeptide enrichment. The streamlined EVGpro platform identified up to 17 times more EV glycoproteins than ultracentrifugation across seven biofluids, profiling 398 EV glycoproteins from just 1 μL tear. Applied to seminal plasma, EVGpro uncover disease-specific glycoprotein signatures and identified previously unreported subtypes of asthenozoospermia. This robust and scalable approach advances the sensitive detection of disease biomarkers and molecular subtypes from diverse biofluids to enable precision medicine.